Skip to main content

Table 1 Clinical history of the patient together with diagnostic results and treatment

From: A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia

Visit No. Date Methods Hematologic parameters Treatment Results
1 August 2003 GTG, FISH (WCP probes) WBC 327×109/l with 73% neutrophils, 23% lymphocytes, 3% monocytes and 1% eosinophiles. Hgb 11.9 g/dl and Plts 540×109/l. - 46,XX,t(9;22)[20]
2 November 2005 GTG, FISH (BCR/ABL and WCP probes) WBC 7.9×109/l with 66% neutrophils, 31% lymphocytes, 2% monocytes and 1% eosinophiles. Hgb 11.2 g/dl and Plts 371×109/l. Imatinib mesylate at 200 mg/day for overall 12 months 46,XX,t(9;22)[20]
3 November 2006 GTG, FISH (BCR/ABL probe) WBC 6.8×109/l with 64% neutrophils, 33% lymphocytes, 2% monocytes and 1% eosinophiles. Hgb 12.8 g/dl and Plts 305×109/l. Imatinib at 400 mg/day for overall 12 months 46,XX,t(9;22)[20]
4 November 2008; patients interrupted treatment for ~12 months; Nitolib was initiated November 2009 GTG, FISH, RT-PCR, RFLP WBC 15.5×109/l with 54% neutrophils, 43% lymphocytes, 3% monocytes and 1% eosinophiles. Hgb 8.8 g/dl and Plts 215×109/l. Imatinib at 400 mg/day for overall 12 months in the total. 45,XX,t(9;22),+dic(17;18),-17,-18[20]
      b2a2 transcript
      T315I mutation
5 March 2010 GTG, FISH, RT-PCR, RFLP WBC 2.2×109/l with 25% neutrophils, 73% lymphocytes, 1% monocytes and 1% eosinophiles. Hgb 9.5 g/dl and Plts 111x109/l. nilotinib at 800  mg/day for overall 5 months. 45,XX,t(9;22),+dic(17;18),-17,-18 [16]/46,XX,t(9;22)[4]
      co-expression of b2a2 and b3a2 transcript.
      T315I mutation
6 November 2010 The patient passed away under the treatment due to unknown reasons